Clinical Trials Logo

Carcinoma, Adenosquamous clinical trials

View clinical trials related to Carcinoma, Adenosquamous.

Filter by:

NCT ID: NCT01307631 Completed - Clinical trials for Endometrial Adenocarcinoma

Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer

Start date: March 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with recurrent or advanced endometrial cancer. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT01301612 Withdrawn - Carcinoma Clinical Trials

Study of Nimotuzumab, Radiation Therapy and Cisplatin Versus Radiation Therapy and Cisplatin for Treatment of Stage IB e IVA UCC(CORUS)

Start date: January 2011
Phase: Phase 2
Study type: Interventional

The primary study objective will be to assess the efficacy of the combination of radiation therapy with nimotuzumab and cisplatin, as compared to the combination of radiation therapy plus cisplatin in the treatment of Uterine Cervical Carcinoma (UCC). The secondary study objectives will be safety and tolerability evaluations, to determine treatment feasibility and the interim efficacy evaluation according to other parameters routinely used in oncology.

NCT ID: NCT01295502 Active, not recruiting - Clinical trials for Cervical Adenocarcinoma

Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer

Start date: April 4, 2011
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and the best dose of paclitaxel and carboplatin after cisplatin and radiation therapy in treating patients with stage IB-IVA cervical cancer. Drugs used in chemotherapy, such as cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving paclitaxel and carboplatin after cisplatin and radiation therapy may kill more tumor cells.

NCT ID: NCT01281852 Completed - Clinical trials for Cervical Adenocarcinoma

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Start date: March 14, 2011
Phase: Phase 1
Study type: Interventional

This phase I clinical trial studies the side effects and best dose of veliparib when given together with paclitaxel and cisplatin and to see how well they work in treating patients with cervical cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment or that has come back. Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving more than one drug (combination chemotherapy) and giving chemotherapy together with veliparib may kill more tumor cells.

NCT ID: NCT01267253 Completed - Clinical trials for Cervical Adenocarcinoma

Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer

Start date: April 4, 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well brivanib alaninate works in treating patients with cervical cancer that has come back. Brivanib alaninate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.

NCT ID: NCT01266460 Completed - Clinical trials for Cervical Adenocarcinoma

Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer

Start date: May 23, 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well vaccine therapy works in treating patients with cervical cancer that does not go to remission despite treatment (persistent) or has come back (recurrent). Vaccines therapy may help the body build an effective immune response to kill tumor cells.

NCT ID: NCT01266447 Completed - Clinical trials for Cervical Adenocarcinoma

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

Start date: February 2011
Phase: Phase 2
Study type: Interventional

This phase II clinical trial is studying the how well veliparib, topotecan hydrochloride, and filgrastim or pegfilgrastim work in treating patients with persistent or recurrent cervical cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by blocking them from dividing. Giving veliparib with chemotherapy may kill more tumor cells. Filgrastim or pegfilgrastim may cause the body to make more blood cells and help it recover from the side effects of chemotherapy.

NCT ID: NCT01210222 Completed - Clinical trials for Endometrial Adenocarcinoma

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

Start date: June 6, 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well trebananib works in treating patients with persistent or recurrent endometrial cancer. Trebananib may stop the growth of endometrial cancer by blocking blood flow to the tumor.

NCT ID: NCT01132820 Completed - Clinical trials for Endometrial Adenocarcinoma

Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer

Start date: June 2010
Phase: Phase 2
Study type: Interventional

This phase II trial studies the side effects and how well cediranib maleate works in treating patients with endometrial cancer that has failed to respond to initial chemotherapy or has come back after surgery, radiation therapy, or other forms of treatment. Cediranib maleate may stop the growth of tumor cells by blocking proteins made by tumors that can stimulate growth of tumor cells as well as blood vessels in and around tumors.

NCT ID: NCT01101451 Active, not recruiting - Clinical trials for Cervical Adenocarcinoma

Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery

Start date: April 12, 2010
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies radiation therapy with chemotherapy to see how well they work compared to radiation therapy alone in treating patients with stage I-IIA cervical cancer who previously underwent surgery. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving radiation therapy together with chemotherapy is more effective than radiation therapy alone in treating patients with cervical cancer.